Capital for science that hasn't been done before.
Hartepicar Biosciences is building a pipeline of first-in-class regenerative therapies, backed by long-term investors who share our commitment to rigorous science.
A well-capitalized path to late-stage trials.
All figures on this page are fictional and were invented for a training exercise.
Why Hartepicar.
First-in-class science
Our peptide platform targets repair pathways that existing treatments do not address, giving each program a clear point of difference.
Premium, value-based pricing
Record-setting therapies launch at premium prices supported by long-term outcome data, protecting margins and funding the next generation of research.
Diversified pipeline
Three programs across skin renewal, wound repair, and cellular longevity spread clinical and commercial risk.
Backed by long-term investors.
| Round | Date | Amount | Lead investor |
|---|---|---|---|
| Seed | 2019 | $12M | Tidewater Ventures |
| Series A | 2021 | $48M | Larkspur Health Partners |
| Series B | 2023 | $135M | Ironwood Life Sciences Capital |
| Series C | September 2026 | $240M | Summit Cedar Fund |
Board of directors.
Margaret Ellsworth
Independent director with three decades of experience building specialty therapeutics companies.
Alina Westbrook
Leads Hartepicar's strategy, partnerships, and investor relations.
Raymond Tolliver
Chairs the audit committee. Former finance executive at a global pharmaceutical manufacturer.
Anika Sorensen, M.D.
Chairs the science and clinical committee. Physician-scientist and former head of clinical development.
On the calendar.
- December 3, 2026Fourth-quarter investor update call
- First half of 2027Topline Phase II results for HPC-101
- March 2027Annual meeting of shareholders
Talk to our team.
For corporate presentations, fiscal summaries, or meeting requests, write to the investor relations team.
Forward-looking statements: dates and expectations on this page are fictional and used only for training purposes.